| 0 (0%) | 11-11 17:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.28 |
1-year : | 2.67 |
| Resists | First : | 1.96 |
Second : | 2.28 |
| Pivot price | 1.35 |
|||
| Supports | First : | 1.47 |
Second : | 1.16 |
| MAs | MA(5) : | 1.47 |
MA(20) : | 1.32 |
| MA(100) : | 1.29 |
MA(250) : | 1.54 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 39.3 |
D(3) : | 34.9 |
| RSI | RSI(14): 64.9 |
|||
| 52-week | High : | 2.54 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MNOV ] has closed below upper band by 10.0%. Bollinger Bands are 262% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.62 - 1.63 | 1.63 - 1.64 |
| Low: | 1.43 - 1.44 | 1.44 - 1.45 |
| Close: | 1.6 - 1.61 | 1.61 - 1.62 |
Mon, 10 Nov 2025
Will MNOV stock continue dividend increases - Portfolio Risk Summary & Reliable Price Action Trade Plans - newser.com
Sun, 09 Nov 2025
Is this a good reentry point in MNOV - CEO Change & Smart Allocation Stock Reports - newser.com
Thu, 06 Nov 2025
MediciNova, Inc. Wins Contract Research and Development Innovation Award at BioTech Breakthrough Awards - Quiver Quantitative
Thu, 06 Nov 2025
MediciNova (NASDAQ: MNOV) wins BioTech Breakthrough Contract R&D Award for MN-166 - Stock Titan
Wed, 05 Nov 2025
Will MNOV stock reach Wall Street targets - Portfolio Risk Report & AI Driven Price Predictions - newser.com
Tue, 04 Nov 2025
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 4.208e+007 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 128 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.328e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 679.8 % |
| Return on Equity (ttm) | -15.1 % |
| Qtrly Rev. Growth | 134600 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -51.5 |
| EBITDA (p.s.) | 41477.3 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.04 |
| Price to Cash Flow | 0.74 |
| Dividend | 0 |
| Forward Dividend | 120660 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|